Kiniksa Pharmaceuticals International, plc filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission, reporting condensed consolidated financial results and balance sheet data as of that date.

Key Highlights

  • Total assets reached $983,243 thousand as of September 30, 2026, up from $763,633 thousand at December 31, 2025, according to the filing.
  • Short-term investments rose to $487,098 thousand from $248,478 thousand at year-end 2025, the filing disclosed.
  • Inventory more than doubled to $108,028 thousand from $54,895 thousand at December 31, 2025, per the condensed consolidated balance sheet.
  • Accounts receivable, net, climbed to $30,779 thousand from $15,594 thousand at December 31, 2025, the company reported.
  • Cash and cash equivalents decreased to $81,660 thousand from $165,596 thousand at December 31, 2025, according to the filing.
  • 78,571,705 total ordinary shares were outstanding as of October 23, 2026, comprising four share classes, the registrant disclosed.
  • Kiniksa is classified as a large accelerated filer as indicated on the filing's cover page.

Kiniksa's Balance Sheet Expansion in the Nine Months to September 30, 2026

According to the filing, Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reported total assets of $983,243 thousand as of September 30, 2026, compared with $763,633 thousand at December 31, 2025. The growth was driven primarily by a sharp increase in short-term investments, which reached $487,098 thousand from $248,478 thousand, and by inventory expansion to $108,028 thousand from $54,895 thousand over the same period.

The company disclosed that cash and cash equivalents declined to $81,660 thousand from $165,596 thousand at December 31, 2025, while accounts receivable, net, rose to $30,779 thousand from $15,594 thousand. Total current assets stood at $750,099 thousand as of September 30, 2026, versus $527,177 thousand at year-end 2025, the filing stated. On the liabilities side, accrued collaboration expenses increased to $105,821 thousand from $70,015 thousand, and accrued expenses rose to $57,699 thousand from $42,020 thousand.

As of October 23, 2026, the registrant reported 78,571,705 ordinary shares outstanding in aggregate, consisting of 48,836,965 Class A ordinary shares, 895,158 Class B ordinary shares, 12,781,964 Class A1 ordinary shares, and 16,057,618 Class B1 ordinary shares, each with a nominal value of $0.000273235 per share. The filing also noted that the company's Class A ordinary shares trade on the Nasdaq Global Select Market under the symbol KNSA. The filing contains forward-looking statements, which the company states are subject to risks and uncertainties described in its cautionary language and Annual Report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

Kiniksa Pharmaceuticals International, plc filed a Form 10-Q for the quarter ended September 30, 2026, presenting unaudited condensed consolidated balance sheet data showing total assets of $983,243 thousand and significant changes in cash, investments, inventory, and receivables compared with December 31, 2025.